Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Alpha-lipoic acid attenuates cardiac hypertrophy via downregulation of PARP-2 and subsequent activation of SIRT-1.

Authors: Zhang, Lan  Zou, Jian  Chai, Erqing  Qi, Yongmei  Zhang, Yingmei 
Citation: Zhang L, etal., Eur J Pharmacol. 2014 Dec 5;744:203-10. doi: 10.1016/j.ejphar.2014.09.037. Epub 2014 Sep 30.
Pubmed: (View Article at PubMed) PMID:25281201
DOI: Full-text: DOI:10.1016/j.ejphar.2014.09.037

Alpha-lipoic acid (ALA) has been described as a therapeutic agent for a number of conditions related to cardiovascular disease. However, its role in protecting against cardiac hypertrophy has not been elucidated. In this study, we found that ALA effectively ameliorated cardiac hypertrophy in vivo and in vitro. The mRNA and protein levels of poly (ADP-ribose) polymerase-2 (PARP-2), which were significantly upregulated in heart tissues of abdominal aortic constriction (AAC) rats and cultured cardiomyocytes exposed to angiotensin II(Ang II), were significantly suppressed by ALA treatment. Furthermore, ALA reversed the downregulation of sirtuin 1 (SIRT1) induced by Ang II. However, when cardiomyocytes were co-transfected with PARP-2 plasmid or siRNA for SIRT1, ALA failed to inhibit hypertrophic responses. These observations suggested that ALA attenuated cardiac hypertrophy, at least partially via inhibition of PARP-2 and subsequent activation of SIRT1. These findings may shed new light on the understanding of the cardioprotective effect of ALA.


Disease Annotations
Gene Ontology Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 13514043
Created: 2018-03-21
Species: All species
Last Modified: 2018-03-21
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.